On May 15, 2026, in New Taipei City, Taiwan, Jyong Biotech Ltd. (Nasdaq: MENS) revealed the submission of its annual report on Form 20-F for the fiscal year concluding on December 31, 2025, to the U.S. Securities and Exchange Commission ("SEC") on May 14, 2026. Jyong Biotech is dedicated to developing and commercializing plant-derived therapeutics, showcasing its commitment to the advancement of innovative biotechnology products.